CDT Equity Inc.
CDTCDT Equity Inc. in brief
CDT Equity Inc. is a listed company in the Biotechnology industry, based in Naples, Florida, USA. Its market value was $0 M on 30 October 2026, which makes it the 28,325th largest listed company in the world and the 4,528th largest in the USA on this site. Its shares trade under the symbol CDT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About CDT Equity Inc.
CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., a Delaware corporation, is a data-driven pharmaceutical development, focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The Company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments.
The Company’s strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies with strong, supporting Phase I safety data. Through advanced co-crystallization and solid-form technologies developed at our Cambridge facilities, the Company improves drug properties and extends patent life by up to 20 years. In partnership with Sarborg Limited, the Company also applies AI-powered signature analysis to rapidly identify new therapeutic applications and combinations for existing compounds.
From the company's annual report filed with the US SEC: read the report
CDT Equity Inc. timeline
- 2021
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2023
- ✎Renamed Conduit Pharmaceuticals Inc.Formerly Murphy Canyon Acquisition Corp..
- 2025
- ✎Renamed CDT Equity Inc.Formerly Conduit Pharmaceuticals Inc..
Events of CDT Equity Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,516 (Oct 2026) · #4,531 (Oct 2026)
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-37M | $-39M | — |
| Dec 2024 | — | — | $-15M | $-18M | — |
| Dec 2023 | — | — | $-5M | $-1M | — |
| Dec 2022 | — | — | $-3M | $-5M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-16M | — | — | $-11779.12 | — |
| Dec 2024 | $-10M | $0M | $-10M | — | — |
| Dec 2023 | $-8M | — | — | $-8.92 | — |
| Dec 2022 | $-2M | — | — | $-0.13 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 9, 20268-KCurrent reportOther events
- Nov 4, 20268-KCurrent reportBylaws amended
- Oct 27, 2026DEF 14AProxy statement
- Oct 27, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure
- Oct 13, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale
- Sep 25, 20268-KCurrent reportBylaws amended · Regulation FD disclosure
- Sep 18, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale
- Sep 8, 2026S-1IPO registration
- Sep 4, 20268-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale
- Sep 1, 20268-KCurrent reportOther events
- Sep 1, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Aug 21, 20268-K/ACurrent report (amended)
Official filings of CDT Equity Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-37 M
- Net income
- $-39 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $6 M
- Total liabilities
- $13 M
- Total equity
- $-7 M
As of December-2025
Top 2 institutional investors in CDT Equity Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | StoneX Group Inc. | 11,952 | New | 0.19% | $0 M | Nov 3, 2026 |
| 2 | Tower Research Capital LLC (TRC) | 105 | New | 0.00% | $0 M | Nov 16, 2026 |
Insider trading at CDT Equity Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Andrew Regan10% owner | Other | +499,616 | — | — | 499,618 | Form 4 |
| filed | Andrew Regan10% owner | Otherindirect | +1.35 M | — | — | 1.35 M | Form 4 |
| filed | Andrew ReganChief Executive Officer, Director, 10% owner | Otherindirect · amended | +543,683 | — | — | 569,322 | Form 4/A |
| filed | Andrew ReganChief Executive Officer, Director, 10% owner | Sellindirect · amended | -29 | — | — | 569,322 | Form 4/A |
| filed | Andrew ReganChief Executive Officer, Director | Otherindirect | +5.44 M | — | — | 5.69 M | Form 4 |
| filed | Andrew ReganChief Executive Officer, Director | Sellindirect | -290 | — | — | 5.69 M | Form 4 |
| filed | Prospect Capital Securities Ltd10% owner | Sellindirect | -5,000 | $0.710 | $4 K | 1.46 M | Form 4 |
| filed | Prospect Capital Securities Ltd10% owner | Sellindirect | -1.46 M | $1.440 | — | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: CDT Equity Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q2 2023 | Q2 2023 | $0.2M |
| Q1 2023 | Q1 2023 | $113.8M |
Trading halts
- 2026-11-06 14:38 UTC, code LUDP, resumed 14:43 UTC
- 2026-11-06 00:50 UTC, code T3, resumed 14:00 UTC
- 2026-09-28 23:50 UTC, code T3, resumed 13:00 UTC
- 2026-07-17 23:50 UTC, code T3, resumed 13:00 UTC
- 2026-06-18 17:00 UTC, code LUDP, resumed 17:05 UTC
Fails to deliver
- : 57,457 shares at $0.08
- : 98,166 shares at $0.08
- : 50,151 shares at $0.08
- : 22,943 shares at $0.19
- : 106,746 shares at $0.24
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
CDT Equity Inc. scorecard#
Passes 1 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growthnot known
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 1
- ✗Profitable in the newest year-$39 MNet income -$39 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.3×Current ratio 0.34 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-183.8×Operating income -183.8 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- ✓Dividends and buybacks above 3% of the market value73.3%Dividends and buybacks were 73.3% of the market value.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
CDT Equity Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 |
|---|---|---|---|---|---|
| Income statement | |||||
| Research and development | 5,054+49.6%— | 3,378+3653%— | 90+143%— | 37—— | |
| General and administrative | 31,703+163%— | 12,041+133%— | 5,172+69.6%— | 3,049r1,093—— | |
| Operating expenses | 36,757+138%— | 15,419+193%— | 5,262+66.5%— | 3,160—— | |
| Operating income | −36,757—— | −15,419—— | −5,262—— | −3,160r−1,203—— | |
| Interest and finance income | — | — | 15−99.2%— | 1,976—— | |
| Interest expense and finance costs | 200+525%— | 32r40—— | 0−100%— | 100—— | |
| Other non-operating income (expense) | −2,467—— | −2,383−150%— | 4,727—— | −1,727r1,976—— | |
| Income before tax | −39,224—— | −17,802—— | −536−169%— | 774—— | |
| Income tax | — | — | — | 375—— | |
| Net income attributable to shareholders | −39,224—— | −17,802—— | −535—— | −4,887r399—— | |
| Earnings per share, basic | -1,177.89—— | -61,598.62r-20.53—— | -0.79r-0.01—— | -0.13—— | |
| Earnings per share, diluted | -1,177.89—— | -61,598.62r-20.53—— | -8.92r-0.09—— | -0.13—— | |
| Shares, weighted average (basic) | 0.0+11422%— | 0.0r0.9−100.0%— | 0.7r67−98.2%— | 37—— | |
| Shares, weighted average (diluted) | 0.0+11422%— | 0.0r0.9−100.0%— | 0.7r68−98.2%— | 37—— | |
| Balance sheet | |||||
| Cash and cash equivalents | 1,509+172%26.7% | 554−86.9%13.2% | 4,228+1123%58.5% | 346—6916% | |
| Short-term investments | — | 600r4,200−85.7%14.3% | 4,200—58.1% | — | |
| Other current assets | 1,823+2.4%32.3% | 1,781r2,161+18.3%42.5% | 1,505—20.8% | — | |
| Current assets | 4,379+61.3%77.5% | 2,715−52.6%64.8% | 5,733+787%79.4% | 647—12933% | |
| Property, plant and equipment | 269+573%4.8% | 40—1.0% | — | — | |
| Right-of-use (leased) assets | 142−46.0%2.5% | 263—6.3% | — | — | |
| Other intangible assets | — | — | — | 5.0—100% | |
| Total assets | 5,650+34.7%100% | 4,193−42.0%100% | 7,224+144380%100% | 5.0r137,518—100% | |
| Accounts payable | 1,913+34.0%33.9% | 1,428+564%34.1% | 215—3.0% | — | |
| Current liabilities | 12,820+19.4%227% | 10,741+496%256% | 1,801−56.9%24.9% | 4,176r418—83520% | |
| Lease liabilities (non-current) | — | 107—2.6% | — | — | |
| Total liabilities | 12,820+16.7%227% | 10,986+43.0%262% | 7,681−23.9%106% | 10,094r5,047—201880% | |
| Retained earnings | −68,325—−1209% | −29,101—−694% | −11,299—−156% | −10,770r−4,300—−215400% | |
| Shareholders' equity | −7,170—−127% | −6,793—−162% | −457—−6.3% | −10,089r−4,300—−201780% | |
| Total liabilities and equity | 5,650+34.7%100% | 4,193−42.0%100% | 7,224+144380%100% | 5.0r137,518—100% | |
| Shares outstanding | 0.0r0.1+1899%— | 0.0r1.4−99.9%— | 0.7r74−98.9%— | 65—— | |
| Cash-flow statement | |||||
| Share-based compensation | 2,183+33.8%— | 1,632+720%— | 199—— | — | |
| Cash from operating activities | −15,555—— | −9,682—— | −7,725—— | −2,266r−1,311—— | |
| Capital expenditure | — | −51—— | — | — | |
| Cash from investing activities | −808—— | −43−106%— | 725—— | −183r−134,895—— | |
| Shares issued | 19,699+492%— | 3,328+2119%— | 150—— | — | |
| Shares bought back | −106—— | — | — | — | |
| Cash from financing activities | 17,422+187%— | 6,067−44.5%— | 10,929+346%— | 2,448r136,504—— | |
| Change in cash | 955—— | −3,674−187%— | 4,228+1323%— | 297—— | |
| Report | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 3.4−44.0%— | 0.3−83.8%— | 0.8−15.1%— | 0.7*+465%— | 1.5−50.5%— | 1.9+7340%— | 0.9r1.3+616%— | 0.1*—— | 3.1—— | 0.0—— | 0.1—— | — | — | |
| General and administrative | 31+165%— | 2.7−12.7%— | 2.9+6.6%— | 20*+504%— | 5.5+102%— | 3.1−0.7%— | 2.7−4.5%— | 3.4*+44.5%— | 2.7+532%— | 3.1—— | 2.8—— | 2.3*—— | 0.4r1.1—— | |
| Operating expenses | 35+94.8%— | 3.0−39.4%— | 3.7+1.1%— | 21*+502%— | 7.0+21.0%— | 5.0+57.7%— | 3.6r4.0+22.4%— | 3.5*+44.6%— | 5.8+1251%— | 3.1—— | 3.0—— | 2.4*—— | 0.4r1.1—— | |
| Operating income | −35—— | −3.0—— | −3.7—— | −21*—— | −7.0—— | −5.0—— | −3.6r−4.0—— | −3.5*—— | −5.8—— | −3.1—— | −3.0—— | −2.4*—— | −0.4r−1.1—— | |
| Interest and finance income | — | — | — | — | — | — | — | — | 0*—— | 0.0—— | 0.0—— | — | — | |
| Interest expense and finance costs | — | — | — | 0*—— | 0.1−67.6%— | 0.1−16.0%— | 0.1−16.0%— | — | 0.3+557%— | 0.1—— | 0.1—— | — | 0.0—— | |
| Other non-operating income (expense) | −2.3—— | −1.6—— | −0.4—— | −0.2*−115%— | −0.1—— | −1.1—— | −1.1—— | 1.1*−58.6%— | −0.7−121%— | −2.2—— | −0.6—— | 2.7*—— | 3.1—— | |
| Net income attributable to shareholders | −37—— | −4.6—— | −4.1—— | −21*—— | −7.1—— | −6.0—— | −4.8r−5.1—— | −2.4*−1082%— | −6.5−346%— | −5.4—— | −3.6—— | 0.2*—— | 2.6r2.0—— | |
| Earnings per share, basic | — | -8.71—— | -5.56—— | — | -13.16—— | -10,940.11r-5.46—— | -3,670.27r-1.32—— | — | -889.58r-0.07−2224050%— | -109.33r-0.07—— | -4.81r-0.05—— | — | 0.04r0.03—— | |
| Earnings per share, diluted | — | -8.71—— | -5.56—— | — | -13.16—— | -10,940.11r-5.46—— | -3,670.27r-1.32—— | — | -889.58r-0.07−8895900%— | -109.33r-0.07—— | -4.81r-0.05—— | — | 0.01r0.00—— | |
| Shares, weighted average (basic) | 0.5+96633%— | 0.5+96633%— | 0.7+56306%— | — | 0.5+7347%— | 0.0r1.1−98.9%— | 0.0r3.9−99.8%— | — | 0.0r87−100.0%— | 0.0r74—— | 0.7r74—— | — | 65—— | |
| Shares, weighted average (diluted) | 0.5+96633%— | 0.5+96633%— | 0.7+56306%— | — | 0.5+7347%— | 0.0r1.1−98.9%— | 0.0r3.9−99.8%— | — | 0.0r87−100.0%— | 0.0r74—— | 0.7r74—— | — | 66r66—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.7—0.6% | 0.7−77.6%0.6% | 0.1−95.4%0.1% | 1.5+172%26.7% | 3.8+5306%44.9% | 3.3+1421%41.7% | 2.1+15.5%27.6% | 0.6−86.9%13.2% | 0.1−99.2%2.4% | 0.2—6.6% | 1.8—37.5% | 4.2—58.5% | 8.6—71.9% | |
| Short-term investments | — | — | — | — | — | — | 0.6—7.8% | 0.6r4.2−85.7%14.3% | — | — | — | 4.2—58.1% | — | |
| Receivables | — | — | — | — | — | — | — | — | 0.5—17.5% | — | — | — | — | |
| Other current assets | 1.2—0.9% | 1.2−10.3%0.9% | 2.1+20.9%1.6% | 1.8+2.4%32.3% | 1.2−4.5%13.9% | 1.3+2425%16.1% | 1.7+1414%22.4% | 1.8r2.2+18.3%42.5% | 1.2−30.8%41.6% | 0.1—1.5% | 0.1—2.3% | 1.5—20.8% | 1.8—15.0% | |
| Current assets | 2.9—2.3% | 2.9−54.0%2.3% | 3.1−48.7%2.4% | 4.4+61.3%77.5% | 7.1+408%83.0% | 6.4+299%79.9% | 5.9+88.5%77.1% | 2.7−52.6%64.8% | 1.4−86.6%46.7% | 1.6—48.4% | 3.2—64.2% | 5.7—79.4% | 10—86.9% | |
| Property, plant and equipment | 0.2—0.1% | 0.2−58.5%0.1% | 0.2−50.9%0.2% | 0.3+573%4.8% | 0.3+577%3.8% | 0.4+662%4.8% | 0.4r0.0—5.6% | 0.0—1.0% | 0.0—1.6% | 0.1—1.5% | — | — | — | |
| Right-of-use (leased) assets | 0.1—0.1% | 0.1−68.6%0.1% | 0.1−53.4%0.1% | 0.1−46.0%2.5% | 0.2−33.6%2.3% | 0.2−36.1%2.6% | 0.2−32.4%3.0% | 0.3—6.3% | 0.3—9.8% | 0.3—9.7% | 0.3—7.0% | — | — | |
| Other intangible assets | — | — | — | — | — | — | 0.4—5.2% | — | — | — | — | — | 0.0—0.0% | |
| Investments in associates | 123—97.0% | 123—97.0% | 123—96.7% | — | — | — | — | — | — | — | — | — | — | |
| Total assets | 127—100% | 127+1486%100% | 127+1547%100% | 5.7+34.7%100% | 8.6+186%100% | 8.0+142%100% | 7.7r7.3+56.9%100% | 4.2−42.0%100% | 3.0−75.1%100% | 3.3—100% | 4.9—100% | 7.2—100% | 12—100% | |
| Accounts payable | 3.7—2.9% | 3.7+197%2.9% | 2.4+238%1.9% | 1.9+34.0%33.9% | 0.6−67.7%7.2% | 1.3+17.8%15.7% | 0.7+510%9.3% | 1.4+564%34.1% | 1.9+5314%63.3% | 1.1—32.2% | 0.1—2.4% | 0.2—3.0% | 0.0—0.3% | |
| Current liabilities | 23—18.4% | 23+429%18.4% | 22+376%17.0% | 13+19.4%227% | 4.3−64.4%49.9% | 4.4−48.7%55.2% | 4.5−41.1%59.0% | 11+496%256% | 12+160%400% | 8.6r2.9—260% | 7.7r2.0—157% | 1.8—24.9% | 4.6—38.3% | |
| Lease liabilities (non-current) | — | — | — | — | 0.0−92.7%0.1% | 0.0−67.4%0.6% | 0.1−54.4%1.0% | 0.1—2.6% | 0.1—3.7% | 0.1—4.3% | 0.2—3.5% | — | — | |
| Total liabilities | 24—18.6% | 24+429%18.6% | 22+367%17.0% | 13+16.7%227% | 4.3−64.7%50.0% | 4.5−49.1%55.8% | 4.6−42.2%60.1% | 11+43.0%262% | 12−7.5%405% | 8.8—265% | 8.0—163% | 7.7—106% | 13—109% | |
| Retained earnings | −77—−60.8% | −77—−60.8% | −72—−57.0% | −68—−1209% | −47—−550% | −40—−499% | −34r−34—−439% | −29—−694% | −27—−892% | −20—−612% | −15—−302% | −11—−156% | −12r−13—−96.1% | |
| Shareholders' equity | 103—81.4% | 103+2821%81.4% | 105+3324%83.0% | −7.2—−127% | 4.3—50.0% | 3.5—44.2% | 3.1r2.7—39.9% | −6.8—−162% | −9.1—−305% | −5.5—−165% | −3.1r−3.1—−63.0% | −0.5—−6.3% | −1.1—−9.0% | |
| Total liabilities and equity | 127—100% | 127+1486%100% | 127+1547%100% | 5.7+34.7%100% | 8.6+186%100% | 8.0+142%100% | 7.7r7.3+56.9%100% | 4.2−42.0%100% | 3.0−75.1%100% | 3.3—100% | 4.9—100% | 7.2—100% | 12—100% | |
| Shares outstanding | 0.6—— | 0.6−73.6%— | 4.7−50.4%— | 0.0r0.1+1899%— | 1.3−98.7%— | 2.4−96.8%— | 9.5—— | 0.0r1.4−99.9%— | 96+31.8%— | 74—— | — | 0.7r74—— | 73—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 2.2+96.7%— | 0.2*+25.0%— | 0.2−15.4%— | 0.2*−41.7%— | 1.6*+343%— | 0.2*−66.9%— | 0.2−45.7%— | 0.4*+91.5%— | 0.4*+3460%— | 0.5*—— | 0.4—— | 0.2*—— | 0.0—— | |
| Cash from operating activities | −11—— | −0.5*—— | −1.9—— | −4.6*—— | −4.4*—— | −2.6*—— | −3.9r−4.3—— | −3.8*—— | −2.0*—— | −1.5*—— | −2.4—— | −4.8*—— | −0.5r−1.7*—— | |
| Capital expenditure | — | — | — | — | — | −0.0*—— | −0.4r−0.0—— | 0*—— | −0.0*—— | — | — | — | — | |
| Cash from investing activities | — | — | — | 0.6*+600%— | −1.0*−1140%— | −0.0*—— | −0.4r−0.0—— | 0.1*−82.9%— | 0.1*+43.3%— | — | — | 0.5*—— | 0.1r−114*—— | |
| Shares issued | — | — | — | 1.7*—— | 6.0*—— | 3.9*—— | 8.1—— | — | — | — | — | −0.0*—— | — | |
| Cash from financing activities | 9.4−39.8%— | 1.2*−68.4%— | 0.5−91.8%— | 1.7*−58.6%— | 6.0*+244%— | 3.8*—— | 5.9—— | 4.2*—— | 1.7*−80.9%— | — | — | −0.4*—— | 9.1r125*—— | |
| Change in cash | −2.6−183%— | 0.7*−45.9%— | −1.4−190%— | −2.3*−582%— | 0.5*—— | 1.2*—— | 1.6—— | 0.5*—— | −0.1*−102%— | −1.6*—— | −2.4—— | −4.4*—— | 8.7*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q/A | 10-K | 10-Q | 10-Q/A | 10-Q/A | 10-K | 10-Q/A | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at CDT Equity Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 1 · Auditor changed 1 · Acquisition or sale completed 2 · Directors and officers 2 · Material agreement 14 · New debt 7 · Unregistered share sale 13 · Shareholder rights changed 5 · Bylaws or fiscal year changed 5 · Shareholder vote 2
| Filed | What happened | Filing |
|---|---|---|
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Acquisition or sale completed | 8-K/A | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Acquisition or sale completed | 8-K/A | |
| Material agreementUnregistered share sale | 8-K | |
| Unregistered share sale | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementNew debt | 8-K | |
| Auditor changed | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026
How CDT Equity Inc. compares in Biotechnology
- Market cap$0 M · higher than 0% of 726
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| CDT Equity Inc.🇺🇸 | $0 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at CDT Equity Inc.? Verify and update this profile — free
Show CDT Equity Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.